Hawton, A;
Goodwin, E;
Boddy, K;
Freeman, J;
Thomas, S;
Chataway, J;
Green, C;
(2020)
Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years.
Multiple Sclerosis Journal
10.1177/1352458520954172.
(In press).
Preview |
Text
Hawton_annie_MSJ_1352458520954172.pdf - Published Version Download (118kB) | Preview |
Abstract
Background: It is a familiar story. A promising multiple sclerosis (MS) treatment clears the three regulatory hurdles of safety, quality and efficacy, only to fall at the fourth: cost-effectiveness. This has led to concerns about the validity of the measures typically used to quantify treatment effects in cost-effectiveness analyses and in 2012, in the United Kingdom, the National Institute for Health and Care Excellence called for an improvement in the cost-effectiveness framework for assessing MS treatments. Objective and Methods: This review describes what is meant by cost-effectiveness in health/social care funding decision-making, and usual practice for assessing treatment benefits. Results: We detail the use of the quality-adjusted life-year (QALY) in resource allocation decisions, and set out limitations of this approach in the context of MS. Conclusion: We conclude by highlighting methodological and policy developments which should aid addressing these limitations.
| Type: | Article |
|---|---|
| Title: | Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1177/1352458520954172 |
| Publisher version: | https://doi.org/10.1177/1352458520954172 |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Clinical Neurology, Neurosciences, Neurosciences & Neurology, Multiple sclerosis, cost-effectiveness, quality-adjusted life-years, cost-effectiveness analysis, health-related quality of life, quality of life, STATE CLASSIFICATION-SYSTEM, PREFERENCE-BASED MEASURES, HEALTH, VALUATIONS, UTILITY |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10111585 |
Archive Staff Only
 |
View Item |
